HALIFAX, NS / / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational ...

The rising global incidence of syphilis underscores the risk of transmission through blood transfusions. Treponema pallidum, the pathogen responsible for syphilis, represents a major public health ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

The test enables healthcare professionals to identify HIV-1/2 and syphilis antibodies from a single finger prick sample.

The test detects HIV-1/2 antibodies in finger prick samples and is intended for use by healthcare professionals in any healthcare setting.

HALIFAX, NS / ACCESSWIRE / December 24, 2024 / MedMira Inc. (MedMira) (TSXV:MIR) announced today that it has received today, ...

the Company expects an immediate regulatory license for its Reveal® TP (Syphilis) Antibody Test and its Reveal® G4 HIV-1/2 Antibody Test. With this step, MedMira is able to offer a flexible ...

HALIFAX, NS / ACCESSWIRE / January 9, 2025 / Today, MedMira Inc. (MedMira) (TSXV:MIR) announced that its received investigational testing authorization (ITA) from Health Canada to begin clinical trial ...

The Multiplo TP/HIV rapid test allows healthcare professional to accurately detect both HIV-1/2 and syphilis antibodies with one sample using a simple finger prick that delivers results immediately.